- Definition

Represents the amount of additional payments to be made by the entity upon the achievement of certain development and commercialization milestones under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementAdditionalPaymentsToBeMadeUponAchievementOfCertainDevelopmentAndCommercializationMilestones
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the further license fee payable upon the achievement of certain clinical and regulatory milestones under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementFurtherLicenseFee
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the initial license fee under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementInitialLicenseFee
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the nonrefundable payments made by the entity under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementNonrefundablePaymentMade
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the period for payment of royalties after the date of the first commercial sale in such country of any product including the licensed compound.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementPeriodAfterDateOfFirstCommercialSaleOfProductForPaymentOfRoyalties
Namespace Prefix:	rdus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty as a percentage of net sales of any product by the Company or its sublicensees under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementRoyaltyRate
Namespace Prefix:	rdus_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_EisaiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=rdus_EisaiAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_SCRASSASAndAffiliatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=rdus_SublicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements (Details) € in Millions		1 Months Ended	12 Months Ended
License Agreements (Details) € in Millions	Mar. 09, 2015 USD ($)	Jun. 30, 2006 USD ($)	Dec. 31, 2015 EUR (€)	Dec. 31, 2015 USD ($)
Eisai \| License Agreement
License Agreements
Period after the date of the first commercial sale of the product for license expiration			10 years	10 years
Initial license fee paid		$ 500,000
Eisai \| License Agreement \| Minimum
License Agreements
Payments to be made upon achievement of certain clinical and regulatory milestones				$ 1,000,000
Eisai \| License Agreement \| Maximum
License Agreements
Payments to be made upon achievement of certain clinical and regulatory milestones				20,000,000
Eisai \| Eisai Amendment \| Research and development
License Agreements
Initial license fee paid	$ 400,000
Clinical Trial Services Agreement \| Ipsen
License Agreements
Nonrefundable, non-creditable payment				$ 250,000
Royalty rate (as a percent)			5.00%	5.00%
Clinical Trial Services Agreement \| Ipsen \| Minimum
License Agreements
Additional payments to be made upon achievement of certain development and commercialization milestones			€ 10.0	$ 10,900,000
Period after the date of the first commercial sale of the product for license expiration			10 years	10 years
Clinical Trial Services Agreement \| Ipsen \| Maximum
License Agreements
Additional payments to be made upon achievement of certain development and commercialization milestones			€ 36.0	$ 39,100,000
Clinical Trial Services Agreement \| Ipsen \| Sublicense Agreement \| Maximum
License Agreements
Period after the date of the first commercial sale of the product for license expiration			10 years	10 years